Education
About Us
Working with TipRanks
Follow Us
Advaxis (ADXS)
OTHER OTC:ADXS
ADXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.80
Previous CloseN/A
Volume3.00
Average Volume (3M)1.31K
Market Cap
$2.17M
Enterprise ValueN/A
Total Cash (Recent Filing)$4.88M
Total Debt (Recent Filing)$8.32M
Price to Earnings (P/E)―
Beta-2.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,633,400
10 Day Avg. Volume691
30 Day Avg. Volume1,309
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Advaxis News
ADXS FAQ
What was Advaxis’s price range in the past 12 months?
Advaxis lowest stock price was $0.03 and its highest was $0.80 in the past 12 months.
What is Advaxis’s market cap?
Advaxis’s market cap is $2.17M.
When is Advaxis’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Advaxis’s earnings last quarter?
Currently, no data Available
Is Advaxis overvalued?
According to Wall Street analysts Advaxis’s price is currently Overvalued.
Does Advaxis pay dividends?
Advaxis does not currently pay dividends.
What is Advaxis’s EPS estimate?
Advaxis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advaxis have?
Advaxis has 42,633,400 shares outstanding.
What happened to Advaxis’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Advaxis?
Currently, no hedge funds are holding shares in ADXS
Company Description
Advaxis
Advaxis, Inc. (ADXS) is a biotechnology company focused on the development and commercialization of immunotherapies based on its proprietary Lm platform technology. This platform uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate the immune system to elicit an anti-tumor response. The company's core products aim to address unmet medical needs in oncology, with a pipeline that includes therapies for various cancers such as cervical, head and neck, and prostate cancers.
Technical Analysis
Salarius Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―
Ownership Overview
58.95% Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---